Head/Neck Flashcards
Head and Neck: Workup
H&P: Site specific symptoms, weight. Assess social support, smoking, alcohol. Head and neck exam, noting teeth condition, cranial nerves, mirror and flex laryngoscopy (esp for larynx), palpation of mass in mouth
FNA biopsy of node if possible
Labs: CBC, CMP, TSH
Primary Imaging: CT of the neck, possible MRI
Staging Imaging: CT chest, PET for stage III-IV (i.e. T3 or N1 or above)
Special imaging: direct laryngoscopy with biopsies, consider videostrobe
Special workup: dental, port, PEG tube, nutrition, audiology, speech and swallowing evaluation, smoking cessation / alcohol counseling
Head and Neck: Sim
supine with chin extended, long mask, wire scar.
Consider: bite block, bolus scar for ECE, contrast
Head/Neck: nodal drainage for oropharynx, larynx, hypopharynx, nasopharynx, and oral cavity
Oropharynx: II-IV
Larynx: II-IV
Hypopharynx: II-V and RP
Nasopharynx: II-deep V and RP, ipsi level IB for N+
Oral cavity: IA-IV
Head and Neck: constraints for parotids and submandibular glands
Mean parotid <26 Gy
50% of each parotid<30 Gy
Mean submandibular <39 Gy
Head and Neck: constraints for larynx, pharyngeal constrictors, and cervical esophagus
larynx mean 44Gy, max 66Gy
constrictors 50Gy
cervical esophagus V45 < 33%
Head and Neck: constraints for lips and oral cavity
oral cavity <39
Lips mean <20 Gy, max 50 Gy
Head and Neck: constraints for brachial plexus, temporal lobes, and brainstem/chiasm/optic nerves
Brachial plexus <66 Gy
Temporal lobes <60 Gy
brainstem/chiasm/optic nerves<54 Gy (1cc brainstem to 60 Gy)
Head and Neck: follow up
PET at 3 months if nodes were treated (salvage neck dissection if SUV remains elevated)
post-treatment baseline imaging of primary then every 3-6 mo, TSH every 6-12 mo, speech/hearing/swallowing continued f/u, smoking cessation/alcohol counseling, dental f/u
T1 Larynx: dose and field
63Gy/28fxs (complete within 44 days)
3D: Opposed laterals, bolus if lesion is anterior
sup: thyroid notch
inf: bottom of cricoid
ant: flash
post: ant vertebral bodies
Some rotate gantry to make posterior border non-divergent or place isocenter at anterior edge of vertebral body
T1 Larynx: dosimetry
wedges with heel anteriorly (15-30 degrees), 6MV photons, 95% isodose line to cover the entire cords, no hotspot over 110%
IMRT carotid sparing for young age
Carotid mean <25 Gy, V35<20%
T1 Larynx: 5yr LC and OS
5yr LC 90%
5yr OS 80%
T2 Larynx: dose and field
(only if confined to glottis)
65.25 in 29 fx, finish in <44 days
Sup border: hyoid
Inf border: 1st tracheal ring
T2 Larynx: 5yr LC and OS
5yr LC 75%
5yr OS 60%
contraindications to laryngeal preservation
T4
extension of 1 cm to BOT
Bulky tumor: 3.5 cm3 for glottic and 6cm3 for supraglottic
Poor swallowing or speech
Larynx: 5yr larynx preservation and OS for stage III and IV
5yr larynx preservation:
80% for stage III
60% for stage IV
5yr OS:
45% for stage III
35% for stage IV
Postop Larynx: fields
Postop bed, levels II-VI to bilateral neck
When discussing borders don’t forget that the hyoid and cricoid are removed after larygectomy
Supraglottic cancer: radiation dose and volumes
70/63/56 (2/1.8/1.6) 35 fx
always treat bilateral neck II-IV
Supraglottic cancer: 5yr OS stage I-IV
5yr OS
stage I 50%
stage II 50%
stage III 45%
stage IV 30%
Hypopharynx cancer: dose and volumes for stage III-IV
Three volume: 6996/5940/5412 (2.12/1.8/1.64) 33 fx with chemo
Two volume: 70/56 SIB
Treat bilateral II-VII and RP
If gross nodes were treated, perform PET at 3 months. If disease is still active, recommend neck dissection
Hypopharynx cancer: 5yr OS and laryngeal preservation for stage III-IV
5yr OS 35%
5ry laryngeal preservation 35%
ACR approriateness criteria for unilateral tonsil treatment
T1-2N0-1 oropharynx, less than 1 cm extension to soft palate, and no BOT involvement
On PE make sure to note BOT or soft palate extension, trismus (pterygoid involvement), inability to protrude tongue (T4 deep tongue muscles)
Unilateral tonsil: doses
70/63/56 (2/1.8/1.6) 35 fx
Tonsil cancer: 2yr OS and LC for T1N0 and T2N0
2yr OS 95%
2yr LC:
T1 90%
T2 80%
Oropharynx cancer: options for HPV testing
first test p16
if negative but suspicious then test HPV PCR
Oropharynx cancer: 3yr OS for low/intermediate/high risk groups
3-yr OS:
Low risk 90%
Int risk 70%
High risk 50%
Oral cavity cancer: doses
6996/5940/5412 (2.12/1.8/1.64) 33 fx
Oral cavity cancer: indications for post-op xrt
T2 with greater than 5 mm, T3-4, N+, LVSI, PNI, close/positive margins
Head/neck: postop doses
66 Gy: positive margin or ECE
60 Gy: node positive neck, dissected neck, and intermediate risk (PNI, LVI, T4, close margin)
54Gy: low risk areas, elective neck
Head/neck cancer: 5yr OS with adjuvant chemoradiation on Cooper/Bernier
5yr OS 50%
Nasopharyngeal cancer: workup
typical head/neck workup plus:
MRI, audiology consult, ophthalmoloty consult, check EBV
Nasopharyngeal cancer: usage of EBV
EBV DNA quantitative PCR: used to give surival and distant met prognosis, and monitor treatment response and recurrence. Can get before and after treatment (<1500 copies before treatment is good and undectable after tx is good)
Nasopharyngeal cancer: volumes and dose
6996/5940/5412 (2.12/1.8/1.64) 33 fx (FUSE MRI!!!)
CTV 6996: GTV and gross nodes with 0.5cm expansion
CTV 5940: GTV +1cm, entire nasopharynx, node positive and dissected neck Ib-Vb/RP/RS, special NPX CTV structures known from heavy pimpin
CTV 5412: node negative neck (may exlcude level IV and Vb)
Nasopharyngeal cancer: intermediate risk CTV structures
nasopharynx
anterior 1/3 of clivus
foramen rotundum and ovale
pterygoid fossa
parapharyngeal space
inferior sphenoid sinus
cavernous sinus
posterior nasal cavity
posterior maxillary sinus
inferior soft palate
retropharyngeal lymph nodes
retrostyloid space
Ib-V neck
Nasopharyngeal cancer: chemo dose and schedule
(chemo for T2-4 or N+)
concurrent cisplatin 100mg/m2 q3wk
adjuvant cisplatin 80 and continuous infusion 5FU 1000 x 3 cycles
Nasopharyngeal cancer: constraints for brainstem, spinal cord, chiasm, optic nerves, mandible, brachial plexus, temporal lobes
true brainstem: max 54Gy
brainstem PRV: V60 < 1%
spinal cord: max 45Gy
true chiasm/optic nerve: max 50 Gy
chiasm/optic nerve PRV: max 54Gy
mandible: max 70Gy, V75 < 1cc
brachial plexus: max 66Gy
temporal lobes: max 60Gy
Nasopharyngeal carcinoma: WHO types
WHO type now is simply keratinized or nonkeratinized. Asian types are nearly all nonkeratinized
Old WHO classification:
WHO I: squamous
WHO II: nonkeratinizing
WHO III: undifferentiated, lymphoepithelioma
Nasopharyngeal carcinoma: 5yr OS for T2-4 or N+
5yr OS 70%
Nasopharyngeal cancer: anatomy
learn special nerves (Jacobs, Villaret etc…) and skull base anatomy
Esthesioneuroblastoma: Kadish staging
Kadish Staging:
A: confined to nasal cavity
B: extends to paranasal sinuses
C: beyond nasal cavity or paranasal sinuses
D: lymph nodes or distant mets
Esthesioneuroblastoma: long term OS for Kadish A/B/C
A 70%
B 60%
C 50%
Esthesioneuroblastoma: treatment paradigm
yeah it’s empty, fill it and add a card with xrt volumes
Hard palate salivary tumor: treatment volume
For adenoid cystic hard palate tumor, if tracing PNI cover hard palate, greater and lesser palatine foramen up PPF and at least some of V2 to foramen rotundum and probably vidian canal. For extensive PNI consider covering VII via greater petrosal nerve and more of V2
Melanoma: volumes for nodal sites
Axilla: classic field includes axilla plus SCV. Some omit supraclavicle
Neck: level II down to supraclavicle
Inguinal: inguinal plus ipsilateral pelvic nodes
Merkel cell: target volumes
5 cm margins around the primary site. Smaller margins are accetptable in head and neck, at least 2 cm
If treating nodes, include in between intransit lymphatics (connect primary and lymph nodes)
Cutaneous SCCa: target volumes
2cm margin around tumor, can reduce to 1 cm around eye, use appositional electrons with custom bolus and custom lead blocking, minimal field size 4x4 cm, ENI if large invasive tumor or poorly differentiated
Lip and oral cavity T1
<2cm, DOI <5mm
Lip and oral cavity T2
2-4cm, DOI 5-10mm
Lip and oral cavity T3
>4cm, DOI >10mm
Lip and oral cavity T4a
Lip: invades bone, inferior alveolar nerve, floor of mouth, skin Oral cavity: cortical bone of maxilla or mandible, maxillary sinus, skin
Lip and oral cavity T4b
invades masticator space, pterygoid plates, skull base, or encasing carotid
General H/N Clinical N1
single ipsilateral node <3cm and ENE(-)
General H/N Clinical N2a
single ipsilateral node 3-6cm and ENE(-)
General H/N Clinical N2b
multiple ipsilateral nodes <6cm and ENE(-)
General H/N Clinical N2c
bilateral or contralateral nodes <6cm and ENE(-)
General H/N Clinical N3a
node >6cm and ENE(-)
General H/N Clinical N3b
clinically overt ENE(+)
General H/N Pathological N1
single ipsilateral node <3cm and ENE(-)
General H/N Pathological N2a
single ipsilateral node 3-6cm and ENE(-) OR single ipsilateral node <3cm and ENE(+)
General H/N Pathological N2b
multiple ipsilateral nodes <6cm and ENE(-)
General H/N Pathological N2c
bilateral or contralateral nodes <6cm and ENE(-)
General H/N Pathological N3a
node >6cm and ENE(-)
General H/N Pathological N3b
ENE(+) that doesn’t meet criteria for N2a